Loss of expression of transforming growth factor-β receptors is associated with poor prognosis in prostate cancer patients

TY - JOUR

T1 - Loss of expression of transforming growth factor-β receptors is associated with poor prognosis in prostate cancer patients

AU - Kim, Isaac Yi

AU - Ahn, Han Jong

AU - Lang, Sharon

AU - Oefelein, Michael G.

AU - Oyasu, Ryoichi

AU - Kozlowski, James M.

AU - Lee, Chung

PY - 1998/7

Y1 - 1998/7

N2 - Transforming growth factor β (TGF-β) is a potent inhibitor of proliferation in most cells and exerts its effects through an interaction with membrane receptors type I (TGF-βRI) and type II (TGF-βRII). Recently, we have demonstrated a correlation between the loss of expression of TGF- βRI and TGF-βRII and increasing Gleason score in archival human prostate cancer tissues. To evaluate the potential prognostic value of this observation, the present study investigated the expression of TGF-β receptors in association with disease progression after the initial diagnosis in 52 archival human prostate cancer tissues. The expression of both TGF- βRI and TGF-βRII was correlated with the Gleason score, clinical tumor stage, 4-year survival rate, and serological recurrence rate after radical prostatectomy. Results revealed that there was a significant association between the Gleason score and the loss of expression of TGF-βRI (P < 0.025) and TGF-βRII (P < 0.01). However, only the loss of TGF-βRI expression showed a statistically significant association with the clinical tumor stage (P < 0.05), 4-year survival rate (P < 0.05), and serological recurrence rate after radical prostatectomy (P < 0.025). Therefore, these data indicate that the loss of TGF-βRI expression as measured by immunohistochemical staining may be a potential prognostic marker in prostate cancer patients.

AB - Transforming growth factor β (TGF-β) is a potent inhibitor of proliferation in most cells and exerts its effects through an interaction with membrane receptors type I (TGF-βRI) and type II (TGF-βRII). Recently, we have demonstrated a correlation between the loss of expression of TGF- βRI and TGF-βRII and increasing Gleason score in archival human prostate cancer tissues. To evaluate the potential prognostic value of this observation, the present study investigated the expression of TGF-β receptors in association with disease progression after the initial diagnosis in 52 archival human prostate cancer tissues. The expression of both TGF- βRI and TGF-βRII was correlated with the Gleason score, clinical tumor stage, 4-year survival rate, and serological recurrence rate after radical prostatectomy. Results revealed that there was a significant association between the Gleason score and the loss of expression of TGF-βRI (P < 0.025) and TGF-βRII (P < 0.01). However, only the loss of TGF-βRI expression showed a statistically significant association with the clinical tumor stage (P < 0.05), 4-year survival rate (P < 0.05), and serological recurrence rate after radical prostatectomy (P < 0.025). Therefore, these data indicate that the loss of TGF-βRI expression as measured by immunohistochemical staining may be a potential prognostic marker in prostate cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=0031776562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031776562&partnerID=8YFLogxK

M3 - Article

C2 - 9676836

SN - 1078-0432

VL - 4

SP - 1625

EP - 1630

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 7

ER -